{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:53:52Z","timestamp":1781895232420,"version":"3.54.5"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dana-Farber\/Harvard Cancer Center Kidney SPORE","award":["2P50CA101942-16"],"award-info":[{"award-number":["2P50CA101942-16"]}]},{"name":"Dana-Farber\/Harvard Cancer Center Kidney SPORE","award":["5P30CA006516-56"],"award-info":[{"award-number":["5P30CA006516-56"]}]},{"name":"Kohlberg Chair at Harvard Medical School and the Trust Family"},{"name":"Michael Brigham"},{"name":"Pan Mass Challenge, Hinda and Arthur Marcus Fund"},{"name":"Roger and Kathy Marino Fund for Research Acceleration"},{"name":"Frank Shaughnessy Kidney Cancer Research Fund"},{"name":"Loker Pinard Funds for Kidney Cancer Research at DFCI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The seventh Kidney Cancer Research Summit was held as a hybrid virtual\/in-person event in Boston, MA during July 17-18, 2025. This conference, which aims to help guide the design of kidney cancer clinical trials and research, centers around projects that showcase the most impactful basic, translational, and clinical data evolving in renal cell carcinoma (RCC), and brings together clinical oncologists, physician scientists, translational researchers, and patient advocates. The abstract presentations were published as a supplement in The Oncologist (https:\/\/academic.oup.com\/oncolo\/issue\/30\/Supplement_2). This perspective will provide the layout of the current RCC research landscape as discussed and debated among the stakeholders at the conference as well as more recent updates.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag204","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:53:36Z","timestamp":1779450816000},"source":"Crossref","is-referenced-by-count":0,"title":["The seventh kidney cancer research summit: progress in accelerating cures"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-8824","authenticated-orcid":false,"given":"A Ari","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana","family":"McKay","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Urology, University of California San Diego , San Diego, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-4724","authenticated-orcid":false,"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London , London, EC1M 6BQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-379X","authenticated-orcid":false,"given":"Kevin","family":"Pels","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-9247","authenticated-orcid":false,"given":"Bryan","family":"Lewis","sequence":"additional","affiliation":[{"name":"KidneyCAN , Philadelphia, PA 19118,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-2034","authenticated-orcid":false,"given":"Susan","family":"Poteat","sequence":"additional","affiliation":[{"name":"KidneyCAN , Philadelphia, PA 19118,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-4559","authenticated-orcid":false,"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"2026061914095480500_oyag204-B1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026061914095480500_oyag204-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v12i3.413","article-title":"Hypoxia inducible factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors","volume":"12","author":"Dogra","year":"2025","journal-title":"J Kidney Cancer VHL."},{"key":"2026061914095480500_oyag204-B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/oncolo\/oyad322","article-title":"The 5th kidney cancer research summit: research accelerating cures for renal cell carcinoma in 2023","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist."},{"key":"2026061914095480500_oyag204-B4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib for patients with renal cell carcinoma after progression with prior immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"2026061914095480500_oyag204-B5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"2026061914095480500_oyag204-B6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-23-2274","article-title":"PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from anti-PD-1 therapy in metastatic clear cell renal cell carcinoma patients","volume":"30","author":"Denize","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026061914095480500_oyag204-B7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","article-title":"Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma","volume":"15","author":"Hugaboom","year":"2025","journal-title":"Cancer Discov"},{"key":"2026061914095480500_oyag204-B8","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B9","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","article-title":"IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Taylor","year":"2022","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","article-title":"SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes","volume":"3","author":"Xie","year":"2022","journal-title":"Nat Cancer."},{"key":"2026061914095480500_oyag204-B11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1186\/s12885-023-11162-0","article-title":"A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation","volume":"23","author":"Javaid","year":"2023","journal-title":"BMC Cancer."},{"key":"2026061914095480500_oyag204-B12","doi-asserted-by":"crossref","first-page":"e121522","DOI":"10.1172\/jci.insight.121522","article-title":"Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma","volume":"3","author":"Panda","year":"2018","journal-title":"JCI Insight."},{"key":"2026061914095480500_oyag204-B13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-024-45216-z","article-title":"Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib\/II study BTCRC-GU16-043","volume":"15","author":"Zakharia","year":"2024","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B14","doi-asserted-by":"crossref","first-page":"1061394","DOI":"10.3389\/fimmu.2022.1061394","article-title":"TGF-\u03b2: a novel predictor and target for anti-PD-1\/PD-L1 therapy","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"2026061914095480500_oyag204-B15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","article-title":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial","volume":"32","author":"Yap","year":"2026","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B16","doi-asserted-by":"crossref","first-page":"e55122","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"Elife."},{"key":"2026061914095480500_oyag204-B17"},{"key":"2026061914095480500_oyag204-B18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41586-023-06575-7","article-title":"The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity","volume":"622","author":"Baumgartner","year":"2023","journal-title":"Nature."},{"key":"2026061914095480500_oyag204-B19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","article-title":"IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity","volume":"14","author":"Moynihan","year":"2024","journal-title":"Cancer Discov"},{"key":"2026061914095480500_oyag204-B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0736","article-title":"736 A phase 1\/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies","volume":"11","author":"Moser","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026061914095480500_oyag204-B21","article-title":"Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti\u2013CTLA-4 in renal cell carcinoma","volume":"10","author":"Schoenfeld","year":"2024","journal-title":"JCI Insight."},{"key":"2026061914095480500_oyag204-B22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41591-025-04067-x","article-title":"Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma","volume":"32","author":"Alves Costa Silva","year":"2026","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B23","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","article-title":"Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"30","author":"Ebrahimi","year":"2024","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature."},{"key":"2026061914095480500_oyag204-B26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7150\/jca.31245","article-title":"Blockade of adenosine A2b receptor reduces tumor growth and migration in renal cell carcinoma","volume":"11","author":"Yi","year":"2020","journal-title":"J Cancer."},{"key":"2026061914095480500_oyag204-B27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"key":"2026061914095480500_oyag204-B28","doi-asserted-by":"crossref","first-page":"S1301","DOI":"10.1016\/j.annonc.2025.08.3212","article-title":"2596MO phase Ib\/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study","volume":"36","author":"Beckermann","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914095480500_oyag204-B29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B adenosine receptor antagonist M1069 counteracts immunosuppressive mechanisms of adenosine and reduces tumor growth In vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026061914095480500_oyag204-B30","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1158\/1078-0432.CCR-22-0669","article-title":"A mesenchymal tumor cell state confers increased dependency on the BCL-XL antiapoptotic protein in kidney cancer","volume":"28","author":"Grubb","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026061914095480500_oyag204-B31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41417-025-00953-1","article-title":"BCL-xL dependency in chromophobe renal cell carcinoma","volume":"32","author":"Mahmoud","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"2026061914095480500_oyag204-B32","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.10.693422","article-title":"BCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers","author":"Basuroy","year":"2025","journal-title":"BioRxiv"},{"key":"2026061914095480500_oyag204-B33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clgc.2023.12.003","article-title":"CD70 is consistently expressed in primary and metastatic clear cell renal cell carcinoma","volume":"22","author":"Huang","year":"2024","journal-title":"Clin Genitourin Cancer."},{"key":"2026061914095480500_oyag204-B34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer."},{"key":"2026061914095480500_oyag204-B35","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted allogeneic CAR T-Cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"2026061914095480500_oyag204-B36","doi-asserted-by":"crossref","first-page":"TPS2676","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","article-title":"A phase 1\/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9\u2013engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors","volume":"42","author":"Pal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B37","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2025.43.16_suppl.4508","article-title":"ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): updated results from the phase 1 TRAVERSE study","volume":"43","author":"Srour","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/onco.13628","article-title":"A randomized phase II study of AGS-16C3F versus axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"26","author":"Kollmannsberger","year":"2021","journal-title":"Oncologist."},{"key":"2026061914095480500_oyag204-B39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oncolo\/oyac263","article-title":"Antibody-based therapeutics for the treatment of renal cell carcinoma: Challenges and opportunities","volume":"28","author":"Mahmoud","year":"2023","journal-title":"Oncologist."},{"key":"2026061914095480500_oyag204-B40","doi-asserted-by":"crossref","first-page":"B006","DOI":"10.1158\/1535-7163.TARG-25-B006","article-title":"Abstract B006: preliminary phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)","volume":"24","author":"Pal","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026061914095480500_oyag204-B41","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061914095480500_oyag204-B42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061914095480500_oyag204-B43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026061914095480500_oyag204-B44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2025.43.5_suppl.549","article-title":"Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B45","doi-asserted-by":"crossref","first-page":"LBA418","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): the randomized phase 3 LITESPARK-022 study","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B46","doi-asserted-by":"crossref","first-page":"LBA417","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA417","article-title":"Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti\u2013PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study","volume":"44","author":"Motzer","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2025.10.010","article-title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","volume":"37","author":"Suarez","year":"2026","journal-title":"Ann Oncol"},{"key":"2026061914095480500_oyag204-B48","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: Pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri","year":"2023","journal-title":"Future Oncol"},{"key":"2026061914095480500_oyag204-B49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2025.43.5_suppl.441","article-title":"Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B50","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2025.43.16_suppl.4506","article-title":"Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B51","doi-asserted-by":"crossref","first-page":"110055","DOI":"10.1016\/j.celrep.2021.110055","article-title":"A renal cell carcinoma tumorgraft platform to advance precision medicine","volume":"37","author":"Elias","year":"2021","journal-title":"Cell Rep"},{"key":"2026061914095480500_oyag204-B52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health organization classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"2026061914095480500_oyag204-B53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2022.04.021","article-title":"Impact of MET status on treatment outcomes in papillary renal cell carcinoma: a pooled analysis of historical data","volume":"170","author":"Albiges","year":"2022","journal-title":"Eur J Cancer."},{"key":"2026061914095480500_oyag204-B54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"2026061914095480500_oyag204-B55","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.24.00767","article-title":"Final overall survival analysis of S1500: a randomized, phase II study comparing sunitinib with cabozantinib, crizotinib, and savolitinib in advanced papillary renal cell carcinoma","volume":"42","author":"Barata","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B56","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET-Driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026061914095480500_oyag204-B57","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061914095480500_oyag204-B58","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.22.01414","article-title":"Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"41","author":"Su\u00e1rez","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B59","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell."},{"key":"2026061914095480500_oyag204-B60","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO-25-00234","article-title":"Tumor-Intrinsic and microenvironmental determinants of impaired antitumor immunity in chromophobe renal cell carcinoma","volume":"43","author":"Labaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176743","article-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma","volume":"9","author":"Kapur","year":"2024","journal-title":"JCI Insight."},{"key":"2026061914095480500_oyag204-B62","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature."},{"key":"2026061914095480500_oyag204-B63","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/s41467-022-29905-1","article-title":"A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers","volume":"13","author":"Koppula","year":"2022","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B64","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.chembiol.2023.04.007","article-title":"Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis","volume":"30","author":"Hendricks","year":"2023","journal-title":"Cell Chem Biol"},{"key":"2026061914095480500_oyag204-B65","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41388-025-03562-2","article-title":"Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma","volume":"44","author":"Salem","year":"2025","journal-title":"Oncogene."},{"key":"2026061914095480500_oyag204-B66","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.clgc.2025.102359","article-title":"Targeting KIT with antibody-drug conjugates in chromophobe renal cell carcinoma","volume":"23","author":"Alchoueiry","year":"2025","journal-title":"Clin Genitourin Cancer."},{"key":"2026061914095480500_oyag204-B67","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1200\/JCO.2024.42.16_suppl.4512","article-title":"A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma","volume":"42","author":"Doshi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B68","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular characteristics of TFE3 and TFEB translocation renal cell carcinomas","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"2026061914095480500_oyag204-B69","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41379-021-00858-y","article-title":"Diagnostic utility of one-stop fusion gene panel to detect TFE3\/TFEB gene rearrangement and amplification in renal cell carcinomas","volume":"34","author":"Harada","year":"2021","journal-title":"Mod Pathol"},{"key":"2026061914095480500_oyag204-B70","doi-asserted-by":"crossref","first-page":"100873","DOI":"10.1016\/j.modpat.2025.100873","article-title":"TRIM63 overexpression in FISH-negative MiTF family altered renal cell carcinoma (MiTF RCC)","volume":"38","author":"Mannan","year":"2025","journal-title":"Mod Pathol"},{"key":"2026061914095480500_oyag204-B71","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s42255-025-01218-9","article-title":"Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma","volume":"7","author":"Li","year":"2025","journal-title":"Nat Metab"},{"key":"2026061914095480500_oyag204-B72","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2025.43.16_suppl.4521","article-title":"AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE\/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study","volume":"43","author":"Cost","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B73","doi-asserted-by":"crossref","first-page":"e005445","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer."},{"key":"2026061914095480500_oyag204-B74","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2023.41.16_suppl.4519","article-title":"Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and\/or rhabdoid (S\/R) metastatic non-clear cell renal cell carcinoma (nccRCC): results from the international metastatic renal cell carcinoma database consortium (IMDC)","volume":"41","author":"Labaki","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.euo.2024.02.007","article-title":"Stratification of patients with renal cell carcinoma by the abundance of sarcomatoid features reveals differences in survival and the underlying pathobiology","volume":"7","author":"Salgia","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026061914095480500_oyag204-B76","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell."},{"key":"2026061914095480500_oyag204-B77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B78","first-page":"100640","article-title":"The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma","volume":"33","author":"Hahn","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"2026061914095480500_oyag204-B79","doi-asserted-by":"crossref","first-page":"114350","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"El Zarif","year":"2024","journal-title":"Cell Rep"},{"key":"2026061914095480500_oyag204-B80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2011.03.029","article-title":"Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score","volume":"60","author":"Kutikov","year":"2011","journal-title":"Eur Urol"},{"key":"2026061914095480500_oyag204-B81","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.urology.2023.07.017","article-title":"AI-generated R.E.N.A.L.+ score surpasses human-generated score in predicting renal oncologic outcomes","volume":"180","author":"Abdallah","year":"2023","journal-title":"Urology."},{"key":"2026061914095480500_oyag204-B82","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41467-025-56784-z","article-title":"Artificial intelligence links CT images to pathologic features and survival outcomes of renal masses","volume":"16","author":"Xiong","year":"2025","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.52733\/KCJ18n3-a1","article-title":"What morphology can teach us about renal cell carcinoma clonal evolution","volume":"18","author":"Kapur","year":"2020","journal-title":"Kidney Cancer J"},{"key":"2026061914095480500_oyag204-B84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2022.12.001","article-title":"Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell."},{"key":"2026061914095480500_oyag204-B85","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/0008-5472.CAN-21-2318","article-title":"Intratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learning","volume":"82","author":"Acosta","year":"2022","journal-title":"Cancer Res"},{"key":"2026061914095480500_oyag204-B86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-025-01504-x","article-title":"MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology","volume":"17","author":"Nielsen","year":"2025","journal-title":"Genome Med"},{"key":"2026061914095480500_oyag204-B87","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41467-025-57717-6","article-title":"Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial","volume":"16","author":"Jasti","year":"2025","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B88","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1038\/s41467-024-50369-y","article-title":"A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"2026061914095480500_oyag204-B89","doi-asserted-by":"crossref","first-page":"S1298","DOI":"10.1016\/j.annonc.2025.08.3207","article-title":"2591O efficacy of cabozantinib and nivolumab in cluster 1\/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker","volume":"36","author":"Haake","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914095480500_oyag204-B90","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"key":"2026061914095480500_oyag204-B91","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.23.00699","article-title":"Plasma kidney injury molecule-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061914095480500_oyag204-B92","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914095480500_oyag204-B93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11255-013-0522-z","article-title":"Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma","volume":"46","author":"Zhang","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"2026061914095480500_oyag204-B94","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"2026061914095480500_oyag204-B95","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat Med"},{"key":"2026061914095480500_oyag204-B96","doi-asserted-by":"crossref","first-page":"oyaf276.049","DOI":"10.1093\/oncolo\/oyaf276.049","article-title":"48Immunotherapy response correlates in \u00admetastatic clear cell renal cell carcinoma from circulating cell-free epigenomes","volume":"30","author":"El Hajj Chehade","year":"2025","journal-title":"Oncologist"},{"key":"2026061914095480500_oyag204-B97","doi-asserted-by":"crossref","DOI":"10.1172\/JCI195725","article-title":"Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma","volume":"136","author":"Garinet","year":"2026","journal-title":"J Clin Invest"},{"key":"2026061914095480500_oyag204-B98","year":"2026"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag204\/68377510\/oyag204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag204\/68377510\/oyag204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag204\/68377510\/oyag204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:10:09Z","timestamp":1781892609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag204\/8691854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag204","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,24]]},"article-number":"oyag204"}}